Chengcheng Wang, Peng Wang, Jinxi Wang, Jessie J.J. Wang, Xialong Tu, Yunping Liu, Jia Zheng, Kaixia Lian, Bulak Arpat, Sheng Guo, Rajendra Kumari, Luke Yu
Advances in ADCs formats such as bispecific ADCs, Probody drug conjugates, immune-stimulating ADCs, protein-degrader ADCs and dual-drug ADCs are providing novel approaches to overcome some of the challenges.
In this poster, we show how our integrated ADC platform leverages patient-derived model systems such as organoids, PDX or ex vivo tissue alongside standard cell line systems to better reflect tumor heterogeneity and patient diversity, thus increasing the potential for biomarker identification.
We describe how patient-derived systems can be leveraged for ADC target validation, therapeutic screening, tackling ADC resistance and guiding patient stratification.
Your privacy is important to us.
We'll never share your information.
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy
2024-11-04
2024-11-02
landing_page
15th World ADC San Diego 2024